With the stroke of the president’s pen, a new U.S. appropriations bill becomes law and it’s one that carries good news for psychological science.
Over the last couple months, the U.S.’s budgeting process has been at a standstill while lawmakers have discussed both their visions for an annual government funding plan as well as a relief package aimed at bringing financial support to the many sectors of the country affected by COVID-19. In a positive step for psychological science advocates not to mention the country the appropriations process was completed on December 27, 2020. In addition to bringing funding increases to key science agencies of interest to psychological scientists, the new budget also reflects responses to key topics that APS discussed with Congressional appropriators earlier in 2020.
More than 1 million people vaccinated for Covid-19 29th Dec 2020 | Source: MSN
OUSTON, TX - DECEMBER 22: (EDITORIAL USE ONLY) Medical staff member Gabriel Cervera Rodriguez (2L) and Dr. Joseph Varon (R) work to install a medical tube for IV on a patient s wrist in the COVID-19 intensive care unit (ICU) at the United Memorial Medical
The nearly yearlong coronavirus pandemic has been full of gloomy numbers but Wednesday brought an encouraging one more than 1 million people have received their first shot of a Covid-19 vaccine.
And that reported number is low, because many doses administrated in recent days have yet to be tabulated in the figures from the US Centers for Disease Control and Prevention, the agency said.
Channels Television
Updated December 29, 2020
KIRKLAND, WA – DECEMBER 28: Pharmacists prepare doses of the COVID-19 vaccine at the Life Care Center of Kirkland on December 28, 2020 in Kirkland, Washington. The Life Care Center of Kirkland, a nursing home, was an early epicenter for coronavirus outbreaks in the U.S. Karen Ducey/Getty Images/AFP
Clinical trials to determine the safety and efficacy of a Covid-19 vaccine candidate from American biotech company Novavax have begun in the United States and Mexico, the US National Institutes of Health (NIH) announced Monday.
A similar Phase 3 trial for the same vaccine, called NVX-CoV2373, is also under way in the United Kingdom, where about 15,000 volunteers have been recruited.
The Latest: Colombia not freely vaccinating immigrants yoursun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yoursun.com Daily Mail and Mail on Sunday newspapers.
December 29, 2020
Novavax announced Monday the initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the US and Mexico.
WASHINGTON The American biotechnology company Novavax announced Monday the initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the US and Mexico.
The Phase 3 trial of another investigational COVID-19 vaccine developed by biotechnology company Novavax, Inc., has started enrolling adult volunteers, the US National Institutes of Health (NIH) announced.
In a statement issued on Monday, the NIH said that the randomized, placebo-controlled trial will enroll approximately 30,000 people at some 115 sites in the US and Mexico.
PREVENT-19 will assess the efficacy, safety and immunogenicity of NVX-CoV2373 in the prevention of COVID-19. The two-thirds of enrollees are to receive active vaccine.